Global & Local Literature Monitoring for Adverse Event Detection
Continuous monitoring of scientific literature is a regulatory obligation for Marketing Authorization Holders (MAHs) and a critical component of proactive pharmacovigilance across the drug lifecycle. Timely identification of safety information from published sources supports accurate adverse event reporting and informed benefit-risk assessment.
CareLyft delivers comprehensive global and local literature monitoring for products across clinical development, pre-authorization, and post-marketing stages. Our services are designed to meet region-specific regulatory requirements while ensuring consistency, accuracy, and audit-ready compliance worldwide.
Our Literature Monitoring Capabilities
- Global Literature Screening - Systematic screening of international scientific publications to identify reportable safety information. Enhanced with AI-powered automated content analysis and NLP-based signal detection.
- End-to-End Literature Review - Complete management of literature identification, review, case extraction, and regulatory reporting.
- Strategic Search Design - Development and maintenance of optimized search strategies tailored to product profiles and regulatory expectations.
- Multi-Database Expertise - Proven expertise across leading databases including Embase, PubMed, and client-specified sources. Integration with emerging clinical data platforms and preprint servers for early signal detection.
- Medical Literature Surveillance - Ongoing monitoring and medical assessment of relevant publications to detect emerging safety signals.
- Local Literature Screening - Country-specific literature searches conducted in line with local regulatory requirements.
- Full-Text Procurement & Review - Sourcing, review, and documentation of full-text articles where applicable.
- Certified Translation Services - Accurate translation of literature articles by certified translators to support global compliance.